GENETIC TECHNOLOGIES ADR REP 3 (GENE)

Genetic Tech Sp ADR 

Valor: 26683707 / Symbol: GENE
  • 0.940 USD
  • -2.98% -0.029
  • 13.12.2018 02:00:00
344 posts / 0 new
Letzter Beitrag
Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 08.11.2018
Mitglied seit: 28.09.2007
Kommentare: 3'104

Obersupermegacool, wenn die losgehen ist jeweils Feuerwerk. da muss man immer etwas davon haben. 

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358

Genau. Hier noch die neueste Info:



ASX ANNOUNCEMENT


May 6, 2013


Genetic Technologies Executes Settlement Agreement
with Laboratory Corporation of America Holdings
In compliance with ASX Continuous Disclosure Rules, Genetic Technologies Limited (ASX : GTG;
NASDAQ: GENE) is pleased to report it has now reached an agreement arising under a License
Agreement originally granted to Genzyme Corporation (“Genzyme”), back in September, 2004.
Under that original Agreement, GTG was to be paid consideration, partly in cash and partly in-kind -
which was not fully received by GTG at that time. This then resulted in an arbitration initiated by GTG
against Genzyme. Subsequently, the Agreement with Genzyme was transferred by Genzyme to
Laboratory Corporation of America Holdings (“LabCorp”) of Burlington, North Carolina, USA, and
recently, GTG and LabCorp representatives met in New York under the supervision of an independent
mediator, and a complete settlement of the matter arising from that 2004 License Agreement has now
been achieved.
As is typical under such circumstances, the precise commercial terms of this Settlement Agreement with
LabCorp are covered by formal confidentiality provisions and cannot be disclosed.


FOR FURTHER INFORMATION PLEASE CONTACT
Dr. Mervyn Jacobson
VP, Global Licensing and Intellectual Property
Genetic Technologies Limited
Phone: +61 419 657 915


Gruss,
Simona

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358

Da ist man heute gut im Schuss, bisheriges Tageshoch 2.94. Momentan


last 2.74.

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 08.11.2018
Mitglied seit: 28.09.2007
Kommentare: 3'104


Nun weiss ich auch noch, wieso der Kurs raufgeht:


 


MELBOURNE, AUSTRALIA -- (Marketwired) -- 05/20/13 -- Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that, through its wholly-owned subsidiary Phenogen Sciences Inc., it has executed an agreement with MultiPlan Inc. of Valencia, California, USA, to use the MultiPlan Network, a national complementary network.


MultiPlan created the complementary network concept in 1980, recognizing the emerging trend toward multi-sited workforces and a growing mobility of health plan participants. In excess of 4,800 hospitals, 99,000 ancillary facilities and 700,000 healthcare professionals participate in the network across the entire United States. Approximately 39 million lives access the network.


The agreement with Multiplan is the sixth such credentialing agreement executed between the Company and similar US Preferred Provider Organisations ("PPOs") and increases significantly the total number of covered lives, for which its BREVAGen™ risk assessment test could be adjudicated as "in-network," to more than 62 million.


As detailed in previous ASX announcements, the positive impact of this credentialing activity has been clearly demonstrated in reviewing reimbursement payments received in respect of the BREVAGen™ test since its launch. As reported by the Company in its March 2013 Quarterly Activities Report, the average reimbursement received in respect of claims that were adjudicated as "in-network," was more than 25% higher than the amounts received in respect of claims that were adjudicated as "out of network," with the time taken to collect the funds also being materially shorter.


Credentialing contracts have now been executed between the Company and MultiPlan Network, Three Rivers Provider Network, Prime Health Services, National Preferred Provider Network / PlanCare America / Ohio Preferred Provider Network LLC (NPPN / OPPN), Galaxy Health Network and Fortified Provider Network.


The Company is now actively pursuing additional agreements with other PPOs in order to further extend access to an increased number of covered lives.
 

Emil

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 08.11.2018
Mitglied seit: 28.09.2007
Kommentare: 3'104

Wann gibt es hier wieder News? Der Kurs ist recht stabil, aber ich bin neugierig.


:wink::new_russian:

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358
Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358

Gleich nochmals gute News: Wink


http://www.asx.com.au/asxpdf/20130619/pdf/42gk09z0gxw8sw.pdf


Gruss,
Simona

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358

Info für Interessierte und Investierte:

 

MELBOURNE, AUSTRALIA -- (Marketwired) -- 06/24/13 -- Genetic Technologies Limited (ASX : GTG) (NASDAQ: GENE) announces the publication online in Breast Cancer Research & Treatment on Friday, June 21, 2013 of a study titled, "Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model."
This independent study, which was conducted under the supervision of Prof. John Hopper and first-authored by Dr. Gillian Dite from the Centre for Molecular Epidemiology at the University of Melbourne, investigated the impact of seven single nucleotide polymorphisms (SNPs) on the predictive accuracy of the Breast Cancer Risk Assessment Tool (Gail Model) ("BCRAT"). The authors used the Australian Breast Cancer Family Registry to study a population-based sample of 962 cases aged 35 to 59 years and 463 controls frequency matched for age and for whom genotyping data was available.
These seven SNPs are utilized in the Company's BREVAGen™ breast cancer risk assessment test, and had previously been studied by Mealiffe et al. (J Natl Cancer Inst 102 (21):1618-1627) for an older cohort of cases and controls from the Women's Health Initiative clinical trial in the USA. The new Australian study supports the previous observation of Mealiffe et al. that including information on seven SNPs associated with breast cancer risk improves the discriminatory accuracy of BCRAT, and extends that observation in pre-menopausal women aged 35 to 49 years.

Genetic Technologies is now actively progressing a research program with leading international academic collaborators to confirm these observations in other ethnic populations and to incorporate the full portfolio of currently known common breast cancer susceptibility variants into the BREVAGen™ test.


Gruss,

Simona
 

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 08.11.2018
Mitglied seit: 28.09.2007
Kommentare: 3'104

Bin zurück und bringe etwas News mit. Zeit zum wieder ein Stücklein reinziehen? :idea:


Genetic Technologies Announces Record Number of BREVAGen™ Tests


June Quarter Delivers Growth of 48.6%
Melbourne, Australia; July 1, 2013: Genetic Technologies Limited (ASX : GTG; NASDAQ: GENE)
announces that a record number of BREVAGenTM test samples were received during the quarter ended
June 30, 2013. Total patient samples received during the quarter was 599, representing growth of more
than 48% over the preceding March quarter, demonstrating a significant increasing trend in market traction.
Total BREVAGenTM test samples received during the 2013 financial year was 1,547, representing growth
of more than 272% over the preceding 2012 financial year.
Encouragingly, the quarter on quarter percentage growth in the number of BREVAGenTM samples received
has been progressively increasing in each of the eight completed quarters since the test was launched in
the U.S. market in July 2011. Further, the samples currently being received are generated from a broad
mix of U.S. geographical sales territories, demonstrating the growing acceptance of the test across the
wider market.


 

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358

Smile


Danke für den Wink, wurde bereits erledigt.


Gruss,


Simona

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358

News/Info für Interessierte und Investierte I-m so happy


http://www.asx.com.au/asxpdf/20130710/pdf/42gz7yhw4zkqtx.pdf


Gruss,


Simona


 

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 08.11.2018
Mitglied seit: 28.09.2007
Kommentare: 3'104

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358

Info:


MELBOURNE, AUSTRALIA -- (Marketwired) -- 08/01/13 -- Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE)


Finalised private placement of shares to domestic and overseas institutional and sophisticated investors raising AUD 2,200,000



Proposed Share Purchase Plan ("SPP") to eligible shareholders to raise up to AUD 3,000,000



Proposed issue of Redeemable Convertible Notes to an institutional investor to raise USD 5,000,000



Commercial roll-out of BREVAGen™, the Company's flagship breast cancer risk test, demonstrating growing traction in large U.S. women's health market



Combined fund raising, once complete, expected to provide the Company with resources sufficient to achieve its commercial goals in the U.S.


Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced a private placement of ordinary shares to domestic and overseas institutional and sophisticated investors to raise AUD 2,200,000.


The Company also plans to raise up to an additional AUD 3,000,000 via a share purchase plan ("SPP") to eligible shareholders, and has executed a term sheet providing for the issuance of Redeemable Convertible Notes ("Notes") to an institutional investor, Ironridge Global IV, Ltd. ("Ironridge"), which, when completed, is expected to raise a further USD 5,000,000.


Lodge Corporate Pty. Ltd. acted as Lead Manager on the fund raising with Ladenburg Thalmann & Co. Inc. acting as placement agent on the Notes, which in aggregate will raise up to AUD 10,600,000 (excluding offer costs). Proceeds from the combined fund raising, together with existing cash, will be applied to:


expansion of U.S. distribution for the Company's lead breast cancer test, BREVAGen™;



completion of additional studies to add new ethnicities (Hispanic and African American) and to expand the addressable market for BREVAGen™;



the increase of market awareness for BREVAGen™ through broader and more active key opinion leader and speaker programs;



investment to further improve reimbursement performance; and



general working capital.


The shares to be offered under the private placement ("Placement") and the SPP will be issued at a price of AUD 0.072 per share, representing a 15.3% discount to the last close price (AUD 0.085) prior to the trading halt on 29 July 2013 (AEST), and a 19.1% discount to the 30-day VWAP (AUD 0.089). The Notes to be issued to Ironridge will be convertible into new NASDAQ-traded American Depository Receipts ("ADRs") at a fixed issue price of USD 3.00 per ADR, representing a 26.1% premium to the last closing pricing of of the ADRs on NASDAQ (USD 2.38) prior to the trading halt.


The combined fund raising will be conducted in three tranches, namely:


1. Private Placement - AUD 2,200,000


The placement of 30,555,556 new shares at an issue price of AUD 0.072 per share to raise AUD 2,200,000 will be conducted under the Company's current 15% placement capacity in accordance with ASX Listing Rule 7.1 and accordingly shareholder approval for the private placement is not required. The new shares will rank equally with existing shares and settlement under the Placement is expected to occur on 8 August 2013 (AEST). The Placement shares are expected to be allotted and quoted on the Australian Securities Exchange ("ASX") within one business day of settlement.


2. Share Purchase Plan - AUD 3,000,000


The Company intends to offer a Share Purchase Plan ("SPP" or "Plan") to eligible shareholders to raise up to a further AUD 3,000,000 on the same terms as the Placement, i.e. at an issue price of AUD 0.072 per share, subject to a waiver being received from the ASX which the Company expects to be granted shortly.


The record date for eligible shareholders to participate in the proposed SPP will be 29 July 2013 (the "Record Date"). Eligible shareholders with a registered address in either Australia or New Zealand will be offered the right to take up to AUD 7,500 worth of fully paid ordinary shares in the Company ("SPP Shares"). Participation in the SPP is optional and available irrespective of the number of shares an Eligible Member currently holds in the Company.


The SPP documents are expected to be despatched to shareholders within 14 days of the Record Date. The SPP offer to eligible shareholders will be non-renounceable and entitlements will not be tradable on the ASX or otherwise transferable. Further details concerning the SPP, including the proposed timetable for the SPP, will be the subject of further ASX announcements in due course.


3. Redeemable Convertible Notes Issue - USD 5,000,000


The Company has executed a term sheet dated 26 July 2013 setting the terms and conditions pursuant to which the Company will issue convertible notes to Ironridge to raise USD 5,000,000. The issue of the Notes will be subject to shareholder approval which the Company will seek at a General Meeting scheduled for September 2013 (details of which will be released to the ASX at the appropriate time). The issue is also subject to the completion of certain US regulatory requirements which the Company anticipates will be finalised before the end of October 2013.


The proposed Notes will be convertible into new ADRs (as traded on NASDAQ under the ticker: GENE) at a fixed issue price of USD 3.00 per ADR. Ironridge will have an option to subscribe for an additional USD 5,000,000 of Notes on the same terms, but convertible into ADRs at a fixed issue price of USD 4.00 per ADR, at any time within a six-month period of the date of the definitive documents being executed (known as a "Greenshoe option").


The broad terms of the proposed Notes are as follows:


Angel The Notes will be convertible into ADRs at a fixed issue price of USD 3.00 per ADR, and at USD 4.00 per ADR under the Greenshoe option;


(b) Interest on the Notes will be calculated at an annual rate of 7.5% per annum, which is adjustable in accordance with certain share market price changes, and will accrue until either the conversion or redemption of the Notes;


(c) The Notes do not have a fixed expiry date and may be redeemed for cash by the Company at any time, or converted into ADRs by the Purchaser or (subject to certain conditions) into ADRs by the Company;


(d) The issue and subscription for the Notes is subject to various conditions precedent including the receipt of shareholder approval, registration of the ADRs and ensuring there are sufficient ADRs available for the conversion of the Notes, delivery of certain opinion letters and additional customary equity funding conditions; and


(e) The Noteholder does not have any right to vote at shareholder meetings.


Commenting on the combined fund raising, GTG Chief Executive Officer, Ms. Alison Mew said: "The additional funding, combined with our existing cash reserves and building recurring income streams, should provide the platform to create a vital and sustainable global molecular diagnostics company."


Genetic Technologies confirms that, with the release of this announcement, the Company is in full compliance with its continuous disclosure obligations.


About Genetic Technologies Limited
Genetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (Deoxyribonucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all species. Its business strategy is the global commercialization of its patents through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics portfolio. Genetic Technologies is an ASX and NASDAQ listed company with operations in the USA and Australia. For more information, please visit www.gtglabs.com.


Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.


FOR FURTHER INFORMATION PLEASE CONTACT
Ms. Alison J. Mew
Chief Executive Officer
Genetic Technologies Limited
Phone: +61 3 8412 7000


Laura Forman (USA)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 103


Genetic Technologies Limited
Website: www.gtglabs.com
Email: info@gtglabs.com
ABN 17 009 212 328


Registered Office
60-66 Hanover Street Fitzroy Victoria 3065 Australia


Postal Address
P.O. Box 115 Fitzroy Victoria 3065 Australia


Phone +61 3 8412 7000
Fax +61 3 8412 7040


 


Gruss,


Simona

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 08.11.2018
Mitglied seit: 28.09.2007
Kommentare: 3'104

Weil es mir langweilig ist, nehme ich da wieder mal was rein, so billig sind sie selten. :biggrin::cool:

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358

 

Da geht es mal wieder nett aufwärts. Gibt es schöne News?

Gruss,

Simona

b00n
Bild des Benutzers b00n
Offline
Zuletzt online: 15.07.2016
Mitglied seit: 15.02.2010
Kommentare: 5'227

Simona hat am 23.08.2013 - 19:01 folgendes geschrieben:

 

Da geht es mal wieder nett aufwärts. Gibt es schöne News?

Gruss,

Simona

http://www.asx.com.au/asxpdf/20130822/pdf/42hv12plm5g0v1.pdf

http://www.asx.com.au/asxpdf/20130820/pdf/42hscsqtn8kwjr.pdf

----gesperrt wegen gutmenschentum, wünsche an der stelle allen alles gute, wie immer. http://investorshub.advfn.com/boards/profilea.aspx?user=193864

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358

b00n hat am 23.08.2013 - 21:09 folgendes geschrieben:

Simona hat am 23.08.2013 - 19:01 folgendes geschrieben:

 

Da geht es mal wieder nett aufwärts. Gibt es schöne News?

Gruss,

Simona

http://www.asx.com.au/asxpdf/20130822/pdf/42hv12plm5g0v1.pdf

http://www.asx.com.au/asxpdf/20130820/pdf/42hscsqtn8kwjr.pdf

Danke dir!

 

Gruss,

Simona

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 08.11.2018
Mitglied seit: 28.09.2007
Kommentare: 3'104

Das habe ich letzte Woche umständehalber verpasst. :oops:


Aber immerhin hat sich der Kurs aufwärts bewegt und einigermassen gehalten. Weiter so, mir gefällt es.

Emil

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 08.11.2018
Mitglied seit: 28.09.2007
Kommentare: 3'104

Emil

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 08.11.2018
Mitglied seit: 28.09.2007
Kommentare: 3'104

Das gefällt  :new_russian::happy:

MELBOURNE, AUSTRALIA -- (Marketwired) -- 08/30/13 -- Genetic Technologies Limited (ASX : GTG) (NASDAQ: GENE) is pleased to announce that it has received its Clinical Laboratory Permit from the New York State Department of Health ("DoH"). In late July, the Company's Melbourne laboratories were inspected under New York's DoH Clinical Laboratory Evaluation Program ("CLEP") and, following the two-day audit, it subsequently received a Laboratory Evaluation Report with "No significant deficiencies". Thus, the permit was able to be issued immediately.


This permit allows the Company to test BREVAGen™ from residents of New York State -- a densely populated state of nearly 20 million people -- and completes the out of state licensures allowing the Company to provide testing services to all 50 US states. The Company can now meet requests received from New York physicians to provide the BREVAGen™ test to patients as part of their clinical practice. Phenogen Sciences Inc. (Genetic Technologies' US subsidiary) will be appointing representatives in the near future to cover this state, with a particular emphasis on New York City.


The addition of this important territory will augment the current market adoption, which the Company notes is delivering significant increases in the number of test samples provided to the laboratory during the current quarter to date.


"This is a wonderful endorsement of the quality of our laboratory systems and the validation package provided by our highly qualified staff," said CEO, Ms. Alison Mew. "Importantly, it also allows women across the United States access to BREVAGen™ to deliver comprehensive breast health care."


About Genetic Technologies Limited
Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, non-coding DNA and product patenting. The Company has operations in Australia and the U.S. and is dual-listed on the ASX (Code: GTG) and NASDAQ (Ticker: GENE). Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets. Its U.S. subsidiary, Phenogen Sciences Inc., offers novel predictive testing and assessment tools to help physicians proactively manage women's health. Phenogen's lead product, BREVAGen™, is a first in class, clinically validated risk assessment test for non-familial breast cancer.


For more information, please visit http://www.gtglabs.com and http://www.phenogensciences.com


Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.


FOR FURTHER INFORMATION PLEASE CONTACT
Ms. Alison J. Mew
Chief Executive Officer
Genetic Technologies Limited
Phone: +61 3 8412 7000


Laura Forman (USA)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 103


 

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358
Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358

Unser Australier hat auch mal wieder News zu berichten: Smile


http://www.asx.com.au/asxpdf/20130917/pdf/42jdx0g8hd7g8j.pdf


 


Gruss,


Simona


 

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 08.11.2018
Mitglied seit: 28.09.2007
Kommentare: 3'104

Wenn den Hoffnungen auch Taten folgen, dann könnte es zu einem erneuten Höhenflüglein kommen da, welches ich dann hoffentlich nicht wieder verschlafe wie beim letzten Mal. (Ich hatte eine geschäftliche Sitzung). :oops:


http://www.gtgcorporate.com/wp-content/uploads/2013/09/Termination-of-patent-re-examination-September-2013.pdf

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358

Info/News:


Genetic Technologies' breast cancer test gains users
Tuesday, October 01, 2013 by Proactive Investors



Genetic Technologies' breast cancer risk test known as BREVAGenTM, is gaining traction with a further record number of test samples received during the September 2013 quarter.
 


Genetic Technologies' (ASX : GTG; NASDAQ: GENE) breast cancer risk test known as BREVAGenTM, is gaining traction with a further record number of test samples received during the September 2013 quarter.


Total patient samples received during the quarter was 914, representing growth of more than 52% over the preceding June quarter. The test usage has now gained in the past five quarters.


The usage of the test is expected to continuing on its growth trajectory, with the recent approval from New York State Department of Health, Clinical Laboratory Evaluation Program.


The BREVAGen™ breast cancer risk stratification test is a novel genetic test panel that examines a patient's DNA to detect the absence or presence of certain common genetic variations associated with an increased risk for developing breast cancer.


The test is designed to help physicians assess aggregate breast cancer risk from these genetic markers.


 


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.


 



Gruss,
Simona

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 08.11.2018
Mitglied seit: 28.09.2007
Kommentare: 3'104

Hier dürfte sich endlich einmal wieder etwas tun bezüglich Zulassungen. Es wird sonst langsam langweilig.


http://www.gtgcorporate.com/wp-content/uploads/2013/10/Notice-of-2013-Annual-General-Meeting-Sample-Proxy-Letter-and-Annual-Report.pdf

Emil

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 08.11.2018
Mitglied seit: 28.09.2007
Kommentare: 3'104

Hier ist noch der Jahresbericht per Ende Juni 2013, ausgegeben am 31.10.13. Es ist etwas viel zu lesen, sehr detailiert aber interessant. Ich habe beschlossen, die Aktie zu behalten. Die Revisionsstelle ist auch international bekannt. SmileDirol


http://www.gtgcorporate.com/wp-content/uploads/2013/10/US-Annual-Report-on-Form-20-F-30-June-2013.pdf

sowie

Quarterly Report

http://www.asx.com.au/asxpdf/20131031/pdf/42khwth890jmv7.pdf

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358
Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358

News/Info


Das sollte dem Kurs helfen:


http://www.asx.com.au/asxpdf/20131206/pdf/42lfs72yjc48w9.pdf


 


Gruss,


Simona

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 06.11.2018
Mitglied seit: 19.05.2006
Kommentare: 1'358
Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 08.11.2018
Mitglied seit: 28.09.2007
Kommentare: 3'104

Schön von euch Angenehmes zu erfahren. Darf man auch auf coole Kurse setzen im kommenden Jahr? Das wäre really nice.....


 


23.12.2013 | 15:10


MELBOURNE, AUSTRAL


IA -- (Marketwired) -- 12/23/13 -- Genetic Technologies Limited (ASX : GTG) (NASDAQ: GENE) today announced that the Redeemable Convertible Note (the "Note") described in the Company's ASX announcement dated September 10, 2013, which was subsequently approved by the Company's shareholders at an Extraordinary General Meeting on November 29, 2013, has now been issued.


The Note, which has a face value of USD 5 million, was issued to Ironridge BioPharma Co., a division of institutional investor, Ironridge Global IV, Ltd. ("Ironridge"). Cleared funds amounting to AUD 5,627,462, before the payment of associated costs, have now been received from Ironridge in respect of the Note. A Registration Statement on Form F-3 in respect of the securities covered by the Note has now been filed in the US and an ASX Appendix 3B in respect of the ordinary shares covered by the Note is attached.


"Genetic Technologies is pleased to have finalized this transaction with Ironridge," said Genetic Technologies Chairman Dr. Mal Brandon. "The funds raised from the Note, together with the net proceeds from the recently completed private placement and share purchase plan, adequately position the Company with resources necessary to expand its U.S. operations and continue the growth of its flagship test BREVAGen™. In addition, the funds will be used to complete studies that will add new ethnicities to increase the size of the available market and improve reimbursement performance."


"According to Booz Allen's latest Market Trends in Genetic Services report, the genetic testing market is growing rapidly," said Mr. John Kirkland, Managing Director of Ironridge Global Partners. "Clinical applications remain somewhat limited, while demand from physicians and patients is increasing. We have been following Genetic Technologies for several years and are impressed with the substantial progress they have made in this emerging industry. We are pleased to be able to fund further growth and development."


About Genetic Technologies Limited
Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, non-coding DNA and product patenting. The Company has operations in Australia and the U.S. and is dual-listed on the ASX (Code: GTG) and NASDAQ (Ticker: GENE). Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets. Its U.S. subsidiary, Phenogen Sciences Inc., offers novel predictive testing and assessment tools to help physicians proactively manage women's health. Phenogen's lead product, BREVAGen™, is a first in class, clinically validated risk assessment test for non-familial breast cancer.


For more information, please visit http://www.gtglabs.com and http://www.phenogensciences.com

Emil

Seiten